As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

Over the next five years, we forecast operating profit margin to expand approximately 500 basis points, from 12.6% in 2023 to high double digits, which we think can be achieved with a combination of ...

Its offerings include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI. On May 22, ESPR and Daiichi Sankyo Europe GmbH announced the ...

BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November ...

Tecsys Inc. , a global provider of supply chain management solutions, has been named a "Leader" in the 2024 Nucleus Research WMS Technology Value Matrix. According to the technology research and ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...